Journal Mobile Options
Table of Contents
Vol. 113, No. 3, 2009
Issue release date: May 2009

Differential Expression of Matrix Metalloproteinases and Tissue Inhibitors and Extracellular Matrix Remodeling in Aortic Regurgitant Hearts

Truter S.L. · Catanzaro D.F. · Supino P.G. · Gupta A. · Carter J. · Herrold E.M. · Dumlao T.F. · Borer J.S.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objectives: Myocardial fibrosis in experimental aortic regurgitation (AR) features abnormal fibronectin with normal collagen content, but the relevant degradative processes have not been assessed. Methods: To elucidate these degradative processes, mRNA (Northern) and protein levels (Western) of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), as well as MMP activity (zymography), were measured in cardiac fibroblasts (CF) from New Zealand white rabbits with experimental AR paired with normals (NL). Collagen and fibronectin were quantified by immunohistochemical staining. Results: In AR CF versus NL CF, MMP-2 and -14 mRNA and protein were increased (both p < 0.005), while TIMPs 1–3 were slightly decreased (p < 0.05–0.005; TIMP-4 undetectable). Gelatinase activity in AR CF was 1.7 times that in NL CF (p < 0.005); fibronectinase activity was unaffected. The Jun N-terminal kinase (JNK) inhibitor SP600125 suppressed MMP-2 protein (0.4-fold, p < 0.05) and mRNA (0.7-fold, p < 0.005) in AR CF; MMP-2 levels in NL CF were unaffected. AR MMP-9 mRNA, protein and activity were low and indistinguishable from NL. In left ventricular tissue, fibronectin was increased 1.9-fold (AR vs. NL, p < 0.05). Total AR collagen was indistinguishable from NL, but the collagen III to collagen I isoform ratio decreased (0.4-fold, p < 0.05). Conclusions: Collagen is relatively deficient in AR fibrosis, due at least in part to upregulated MMPs and downregulated TIMPs; fibronectinase is unaltered. JNK-dependent regulation may stimulate both MMP-2 and fibronectin expression in AR, providing a potential therapeutic target.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Jalil JE, Doering CW, Janicki JS, Pick R, Shroff SG, Weber KT: Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 1989;64:1041–1050.
  2. Brilla CG, Janicki JS, Weber KT: Impaired diastolic function and coronary reserve in genetic hypertension. Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 1991;69:107–115.
  3. Weber K, Janicki J, Shroff S, Pick R, Chen R, Bashey R: Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. Circ Res 1988;62:757–765.
  4. Magid N, Opio G, Wallerson D, Young M, Borer J: Heart failure due to chronic experimental aortic regurgitation. Am J Physiol 1994;267:H556–H562.
  5. Borer J, Truter S, Herrold E, Falcone D, Pena M, Carter J, Dumlao T, Lee J, Supino P: Myocardial fibrosis in chronic aortic regurgitation: molecular and cellular responses to volume overload. Circulation 2002;105:1837–1842.
  6. Brower GL, Gardner JD, Forman MF, Murray DB, Voloshenyuk T, Levick SP, Janicki JS: The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg 2006;30:604–610.
  7. Goldfine S, Pena M, Magid N, Liu S, Borer J: Myocardial collagen in cardiac hypertrophy resulting from chronic aortic regurgitation. Am J Ther 1998;5:139–146.
  8. Liu S, Magid N, Fox P, Goldfine S, Borer J: Fibrosis, myocyte degeneration and heart failure in chronic experimental aortic regurgitation. Cardiology 1998;90:101–109.
  9. Leiden JM: The genetics of dilated cardiomyopathy – emerging clues to the puzzle. N Engl J Med 1997;337:1080–1081.
  10. Nagase H, Woessner JF Jr: Matrix metalloproteinases. J Biol Chem 1999;274:21491–21494.
  11. Woessner JF Jr: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145–2154.
  12. Muro AF, Bernath VA, Kornblihtt AR: Interaction of the –170 cyclic AMP response element with the adjacent CCAAT box in the human fibronectin gene promoter. J Biol Chem 1992;267:12767–12774.
  13. Hasan S, Nakajima M: Retinoic acid synergizes with cyclic AMP to enhance MMP-2 basal promoter activity. Biochem Biophys Res Commun 1999;258:663–667.
  14. Li YS, Shyy JY, Li S, Lee J, Su B, Karin M, Chien S: The Ras-JNK pathway is involved in shear-induced gene expression. Mol Cell Biol 1996;16:5947–5954.
  15. Tyagi SC, Lewis K, Pikes D, Marcello A, Mujumdar VS, Smiley LM, Moore CK: Stretch-induced membrane type matrix metalloproteinase and tissue plasminogen activator in cardiac fibroblast cells. J Cell Physiol 1998;176:374–382.
  16. MacKenna D, Dolfi F, Vuori K, Ruoslahti E: Extracellular signal-regulated kinase and c-Jun NH2-terminal kinase activation by mechanical stretch is integrin-dependent and matrix-specific in rat cardiac fibroblasts. J Clin Invest 1998;101:301–310.
  17. Atance J, Yost MJ, Carver W: Influence of the extracellular matrix on the regulation of cardiac fibroblast behavior by mechanical stretch. J Cell Physiol 2004;200:377–386.
  18. Magid NM, Borer JS, Young MS, Wallerson DC, De Monteiro C: Suppression of protein degradation in progressive cardiac hypertrophy of chronic aortic regurgitation. Circulation 1993;87:1249–1257.
  19. Mitra R, Morad M: A uniform enzymatic method for dissociation of myocytes from hearts and stomachs of vertebrates. Am J Physiol 1985;249:H1056–H1060.
  20. Brilla CG, Zhou G, Matsubara L, Weber KT: Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994;26:809–820.
  21. Rodemann H, Muller G: Abnormal growth and clonal proliferation of fibroblasts derived from kidneys with interstitial fibrosis. Proc Soc Exp Biol Med 1990;195:57–63.
  22. Tyagi SC, Campbell SE, Reddy HK, Tjahja E, Voelker DJ: Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts. Mol Cell Biochem 1996;155:13–21.
  23. Xu X, Chen Z, Wang Y, Yamada Y, Steffensen B: Functional basis for the overlap in ligand interactions and substrate specificities of matrix metalloproteinases-9 and -2. Biochem J 2005;392:127–134.
  24. Spinale FG: Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007;87:1285–1342.
  25. Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827–839.
  26. Brower GL, Henegar JR, Janicki JS: Temporal evaluation of left ventricular remodeling and function in rats with chronic volume overload. Am J Physiol 1996;271:H2071–H2078.
  27. Brower GL, Chancey AL, Thanigaraj S, Matsubara BB, Janicki JS: Cause and effect relationship between myocardial mast cell number and matrix metalloproteinase activity. Am J Physiol Heart Circ Physiol 2002;283:H518–H525.
  28. Brower GL, Janicki JS: Contribution of ventricular remodeling to pathogenesis of heart failure in rats. Am J Physiol Heart Circ Physiol 2001;280:H674–H683.
  29. Borer J, Truter S, Herrold E, Supino P, Carter J, Gupta A: The cellular and molecular basis of heart failure in regurgitant valvular diseases: the myocardial extracellular matrix as a building block for future therapy. Adv Cardiol 2002;39:7–14.
  30. Bernardo MM, Fridman R: TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. Biochem J 2003;374:739–745.
  31. Hernandez-Barrantes S, Shimura Y, Soloway PD, Sang QA, Fridman R: Differential roles of TIMP-4 and TIMP-2 in pro-MMP-2 activation by MT1-MMP. Biochem Biophys Res Commun 2001;281:126–130.
  32. Jo Y, Yeon J, Kim HJ, Lee ST: Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system. Biochem J 2000;345:511–519.
  33. Bergman MR, Cheng S, Honbo N, Piacentini L, Karliner JS, Lovett DH: A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. Biochem J 2003;369:485–496.
  34. Truter S, Gupta A, Leer E, Huang Z, Pitlor L, Borer J: The stress-activated protein kinase pathways, C-Jun N-terminal kinase and P38-mitogen activated protein kinase, regulate fibronectin expression in aortic regurgitation. J Am Coll Cardiol 2005;45:353A.

    External Resources

  35. Singhal PC, Sagar S, Garg P: Simulated glomerular pressure modulates mesangial cell 72 kDa metalloproteinase activity. Connect Tissue Res 1996;33:257–263.
  36. Yasuda T, Kondo S, Homma T, Harris RC: Regulation of extracellular matrix by mechanical stress in rat glomerular mesangial cells. J Clin Invest 1996;98:1991–2000.
  37. Maron BJ, Ferrans VJ, Roberts WC: Myocardial ultrastructure in patients with chronic aortic valve disease. Am J Cardiol 1975;35:725–739.
  38. Krayenbuehl HP, Hess OM, Monrad ES, Schneider J, Mall G, Turina M: Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement. Circulation 1989;79:744–755.
  39. Piper C, Schultheiss HP, Akdemir D, Rudolf J, Horstkotte D, Pauschinger M: Remodeling of the cardiac extracellular matrix differs between volume- and pressure-overloaded ventricles and is specific for each heart valve lesion. J Heart Valve Dis 2003;12:592–600.
  40. Polyakova V, Hein S, Kostin S, Ziegelhoeffer T, Schaper J: Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol 2004;44:1609–1618.
  41. Fielitz J, Leuschner M, Zurbrugg HR, Hannack B, Pregla R, Hetzer R, Regitz-Zagrosek V: Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis. J Mol Med 2004;82:809–820.
  42. Heymans S, Schroen B, Vermeersch P, Milting H, Gao F, Kassner A, Gillijns H, Herijgers P, Flameng W, Carmeliet P, Van de Werf F, Pinto YM, Janssens S: Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 2005;112:1136–1144.
  43. Wolffe AP, Matzke MA: Epigenetics: regulation through repression. Science 1999;286:481–486.
  44. Barcellos-Hoff MH: It takes a tissue to make a tumor: epigenetics, cancer and the microenvironment. J Mammary Gland Biol Neoplasia 2001;6:213–221.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50